{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T20:58:18Z","timestamp":1785445098439,"version":"3.56.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T00:00:00Z","timestamp":1785369600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T00:00:00Z","timestamp":1785369600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-026-16153-5","type":"journal-article","created":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T03:43:30Z","timestamp":1785383010000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Combining fruquintinib with TAS-102 as a promising strategy: antitumor activity in preclinical colorectal and gastric cancer xenograft models"],"prefix":"10.1186","volume":"26","author":[{"given":"Takahito","family":"Hara","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megumi","family":"Morimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaaki","family":"Kakehi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Momoko","family":"Kamedani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miyu","family":"Nakayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syunsuke","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsuyoshi","family":"Osaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junpei","family":"Soeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideaki","family":"Bando","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takayuki","family":"Yoshino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,30]]},"reference":[{"issue":"2","key":"16153_CR1","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1161\/hypertensionaha.117.10271","volume":"71","author":"AK Pandey","year":"2018","unstructured":"Pandey AK, Singhi EK, Arroyo JP, Ikizler TA, Gould ER, Brown J, et al. Mechanisms of VEGF (Vascular Endothelial Growth Factor) Inhibitor-Associated Hypertension and Vascular Disease. Hypertension. 2018;71(2):e1\u20138. https:\/\/doi.org\/10.1161\/hypertensionaha.117.10271.","journal-title":"Hypertension"},{"key":"16153_CR2","doi-asserted-by":"publisher","unstructured":"Hsu MC, Pan MR, Hung WC. Two Birds, one stone: double hits on tumor growth and lymphangiogenesis by targeting vascular endothelial growth factor receptor 3. Cells. 2019;8(3). https:\/\/doi.org\/10.3390\/cells8030270.","DOI":"10.3390\/cells8030270"},{"key":"16153_CR3","doi-asserted-by":"publisher","first-page":"248","DOI":"10.3389\/fonc.2018.00248","volume":"8","author":"I Zuazo-Gaztelu","year":"2018","unstructured":"Zuazo-Gaztelu I, Casanovas O. Unraveling the Role of Angiogenesis in Cancer Ecosystems. Front Oncol. 2018;8:248. https:\/\/doi.org\/10.3389\/fonc.2018.00248.","journal-title":"Front Oncol"},{"issue":"4","key":"16153_CR4","doi-asserted-by":"publisher","first-page":"1837","DOI":"10.1152\/physrev.00039.2021","volume":"102","author":"LC Dieterich","year":"2022","unstructured":"Dieterich LC, Tacconi C, Ducoli L, Detmar M. Lymphatic vessels in cancer. Physiol Rev. 2022;102(4):1837\u201379. https:\/\/doi.org\/10.1152\/physrev.00039.2021.","journal-title":"Physiol Rev"},{"issue":"1","key":"16153_CR5","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s13045-019-0718-5","volume":"12","author":"S Qin","year":"2019","unstructured":"Qin S, Li A, Yi M, Yu S, Zhang M, Wu K. Recent advances on anti-angiogenesis receptor tyrosine kinase inhibitors in cancer therapy. J Hematol Oncol. 2019;12(1):27. https:\/\/doi.org\/10.1186\/s13045-019-0718-5.","journal-title":"J Hematol Oncol"},{"issue":"9","key":"16153_CR6","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1038\/nm0901-987","volume":"7","author":"RK Jain","year":"2001","unstructured":"Jain RK. Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat Med. 2001;7(9):987\u20139. https:\/\/doi.org\/10.1038\/nm0901-987.","journal-title":"Nat Med"},{"issue":"18","key":"16153_CR7","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1056\/NEJMoa2214963","volume":"388","author":"GW Prager","year":"2023","unstructured":"Prager GW, Taieb J, Fakih M, Ciardiello F, Van Cutsem E, Elez E, et al. Trifluridine-Tipiracil and Bevacizumab in Refractory Metastatic Colorectal Cancer. N Engl J Med. 2023;388(18):1657\u201367. https:\/\/doi.org\/10.1056\/NEJMoa2214963.","journal-title":"N Engl J Med"},{"issue":"12","key":"16153_CR8","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.4161\/15384047.2014.964087","volume":"15","author":"Q Sun","year":"2014","unstructured":"Sun Q, Zhou J, Zhang Z, Guo M, Liang J, Zhou F, et al. Discovery of fruquintinib, a potent and highly selective small molecule inhibitor of VEGFR 1, 2, 3 tyrosine kinases for cancer therapy. Cancer Biol Ther. 2014;15(12):1635\u201345. https:\/\/doi.org\/10.4161\/15384047.2014.964087.","journal-title":"Cancer Biol Ther"},{"key":"16153_CR9","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1016\/j.jconrel.2025.02.025","volume":"380","author":"Y Yoshioka","year":"2025","unstructured":"Yoshioka Y, Yamamoto S, Kusamori K, Nakayama M, Fujita H, Goto A, et al. Pharmacokinetics and protein binding of cholesterol-conjugated heteroduplex oligonucleotide. J Control Release. 2025;380:787\u201399. https:\/\/doi.org\/10.1016\/j.jconrel.2025.02.025.","journal-title":"J Control Release"},{"issue":"1","key":"16153_CR10","doi-asserted-by":"publisher","first-page":"4228","DOI":"10.1038\/s41598-019-40862-6","volume":"9","author":"CC Yeh","year":"2019","unstructured":"Yeh CC, Shih LJ, Chang JL, Tsuei YW, Wu CC, Hsiao CW, et al. Synchronous vascular endothelial growth factor protein profiles in both tissue and serum identify metastasis and poor survival in colorectal cancer. Sci Rep. 2019;9(1):4228. https:\/\/doi.org\/10.1038\/s41598-019-40862-6.","journal-title":"Sci Rep"},{"key":"16153_CR11","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1186\/1471-2407-10-299","volume":"10","author":"XL Wang","year":"2010","unstructured":"Wang XL, Fang JP, Tang RY, Chen XM. Different significance between intratumoral and peritumoral lymphatic vessel density in gastric cancer: a retrospective study of 123 cases. BMC Cancer. 2010;10:299. https:\/\/doi.org\/10.1186\/1471-2407-10-299.","journal-title":"BMC Cancer"},{"issue":"3","key":"16153_CR12","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1101\/gad.14.3.289","volume":"14","author":"SY Shieh","year":"2000","unstructured":"Shieh SY, Ahn J, Tamai K, Taya Y, Prives C. The human homologs of checkpoint kinases Chk1 and Cds1 (Chk2) phosphorylate p53 at multiple DNA damage-inducible sites. Genes Dev. 2000;14(3):289\u2013300.","journal-title":"Genes Dev"},{"issue":"1","key":"16153_CR13","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1038\/bjc.2015.209","volume":"113","author":"AJ Weickhardt","year":"2015","unstructured":"Weickhardt AJ, Williams DS, Lee CK, Chionh F, Simes J, Murone C, et al. Vascular endothelial growth factor D expression is a potential biomarker of bevacizumab benefit in colorectal cancer. Br J Cancer. 2015;113(1):37\u201345. https:\/\/doi.org\/10.1038\/bjc.2015.209.","journal-title":"Br J Cancer"},{"key":"16153_CR14","doi-asserted-by":"publisher","unstructured":"M\u00e9sange P, Poindessous V, Sabbah M, Escargueil AE, de Gramont A, Larsen AK. Intrinsic bevacizumab resistance is associated with prolonged activation of autocrine VEGF signaling and hypoxia tolerance in colorectal cancer cells and can be overcome by nintedanib, a small molecule angiokinase inhibitor. Oncotarget. 2014;5(13):4709\u201321. https:\/\/doi.org\/10.18632\/oncotarget.1671.","DOI":"10.18632\/oncotarget.1671"},{"issue":"10395","key":"16153_CR15","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/s0140-6736(23)00772-9","volume":"402","author":"A Dasari","year":"2023","unstructured":"Dasari A, Lonardi S, Garcia-Carbonero R, Elez E, Yoshino T, Sobrero A, et al. Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study. Lancet. 2023;402(10395):41\u201353. https:\/\/doi.org\/10.1016\/s0140-6736(23)00772-9.","journal-title":"Lancet"},{"issue":"24","key":"16153_CR16","doi-asserted-by":"publisher","first-page":"2486","DOI":"10.1001\/jama.2018.7855","volume":"319","author":"J Li","year":"2018","unstructured":"Li J, Qin S, Xu RH, Shen L, Xu J, Bai Y, et al. Effect of Fruquintinib vs Placebo on Overall Survival in Patients With Previously Treated Metastatic Colorectal Cancer: The FRESCO Randomized Clinical Trial. JAMA. 2018;319(24):2486\u201396. https:\/\/doi.org\/10.1001\/jama.2018.7855.","journal-title":"JAMA"},{"issue":"5","key":"16153_CR17","doi-asserted-by":"publisher","first-page":"2135","DOI":"10.3892\/or.2015.3876","volume":"33","author":"H Tsukihara","year":"2015","unstructured":"Tsukihara H, Nakagawa F, Sakamoto K, Ishida K, Tanaka N, Okabe H, et al. Efficacy of combination chemotherapy using a novel oral chemotherapeutic agent, TAS-102, together with bevacizumab, cetuximab, or panitumumab on human colorectal cancer xenografts. Oncol Rep. 2015;33(5):2135\u201342. https:\/\/doi.org\/10.3892\/or.2015.3876.","journal-title":"Oncol Rep"},{"issue":"9","key":"16153_CR18","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1016\/j.ctrv.2015.06.001","volume":"41","author":"HJ Lenz","year":"2015","unstructured":"Lenz HJ, Stintzing S, Loupakis F. TAS-102, a novel antitumor agent: a review of the mechanism of action. Cancer Treat Rev. 2015;41(9):777\u201383. https:\/\/doi.org\/10.1016\/j.ctrv.2015.06.001.","journal-title":"Cancer Treat Rev"},{"issue":"1","key":"16153_CR19","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1007\/s00280-014-2471-3","volume":"74","author":"Y Gu","year":"2014","unstructured":"Gu Y, Wang J, Li K, Zhang L, Ren H, Guo L, et al. Preclinical pharmacokinetics and disposition of a novel selective VEGFR inhibitor fruquintinib (HMPL-013) and the prediction of its human pharmacokinetics. Cancer Chemother Pharmacol. 2014;74(1):95\u2013115. https:\/\/doi.org\/10.1007\/s00280-014-2471-3.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"2","key":"16153_CR20","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1159\/000528867","volume":"68","author":"M Nukatsuka","year":"2023","unstructured":"Nukatsuka M, Fujioka A, Nagase H, Tanaka G, Hayashi H. Evaluation of a Novel Combination Therapy, Based on Trifluridine\/Tipiracil and Fruquintinib, against Colorectal Cancer. Chemotherapy. 2023;68(2):102\u201310. https:\/\/doi.org\/10.1159\/000528867.","journal-title":"Chemotherapy"},{"issue":"17","key":"16153_CR21","doi-asserted-by":"publisher","first-page":"13438","DOI":"10.18632\/oncotarget.24412","volume":"9","author":"K Matsuoka","year":"2018","unstructured":"Matsuoka K, Nakagawa F, Kobunai T, Takechi T. Trifluridine\/tipiracil overcomes the resistance of human gastric 5-fluorouracil-refractory cells with high thymidylate synthase expression. Oncotarget. 2018;9(17):13438\u201350. https:\/\/doi.org\/10.18632\/oncotarget.24412.","journal-title":"Oncotarget"},{"issue":"4","key":"16153_CR22","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1158\/1535-7163.Mct-08-0972","volume":"8","author":"JJ Yeh","year":"2009","unstructured":"Yeh JJ, Routh ED, Rubinas T, Peacock J, Martin TD, Shen XJ, et al. KRAS\/BRAF mutation status and ERK1\/2 activation as biomarkers for MEK1\/2 inhibitor therapy in colorectal cancer. Mol Cancer Ther. 2009;8(4):834\u201343. https:\/\/doi.org\/10.1158\/1535-7163.Mct-08-0972.","journal-title":"Mol Cancer Ther"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-16153-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-026-16153-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-16153-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T20:03:20Z","timestamp":1785441800000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12885-026-16153-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,30]]},"references-count":22,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["16153"],"URL":"https:\/\/doi.org\/10.1186\/s12885-026-16153-5","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,30]]},"assertion":[{"value":"15 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All animal studies were conducted in accordance with the study protocols approved by the Institutional Animal Care and Use Committee (IACUC) and in compliance with the Committee\u2019s regulations. The antitumor study using HT\u201129 cells was conducted at KAC Co., Ltd. (Shiga, Japan) and approved under IACUC protocol number 24\u20110608. The antitumor study using COLO-205 cells was conducted at HAMRI Co., Ltd. (Ibaraki, Japan) and approved under IACUC protocol number 24\u2011040. The antitumor study using SC-2-JCK cells was conducted at the Central Institute for Experimental Medicine and Life Science (CIEM) (Kanagawa, Japan) and approved under IACUC protocol number AIA240055\u2011001. The antitumor study using MKN45 cells was conducted at CIEM and approved under IACUC protocol number AIA230115. The intratumoral concentration study using HT\u201129 cells was conducted at KAC Co., Ltd. and approved under IACUC protocol number 24\u20111007.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"909"}}